Insulet Corp
Închisă
SectorSănătate
149.51 0.33
Rezumat
Modificarea prețului
24h
Minim
148.69
Maxim
150.13
Venit | -11M 91M |
|---|---|
Vânzări | -22M 762M |
P/E Medie Sector | 35.482 49.052 |
EPS | 1.3 |
Marjă de profit | 11.96 |
Angajați | 5,400 |
EBITDA | -23M 154M |
Recomandări | Puternic Cumpărare |
|---|---|
Prognoză pe 12 luni | +53.21% upside |
Următoarele câștiguri | 6 aug. 2026 |
|---|
Capitalizare de piață | -1.4B 10B |
|---|---|
Deschiderea anterioară | 149.18 |
Închiderea anterioară | 149.51 |
Sentimentul știrilor
By Acuity
68%
32%
308 / 342 Clasament în Healthcare
Insulet Corp Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Despre Insulet Corp
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.